Antares Pharma Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
20,618.50
26,501.70
45,658.10
52,222.00
54,515.00
63,554
Cost of Goods Sold (COGS) incl. D&A
9,266.00
11,580.50
19,993.50
29,351.10
28,034.00
31,664
Gross Income
11,352.50
14,921.20
25,664.60
22,871.00
26,481.00
31,890
SG&A Expense
32,137.80
48,334.40
46,126.60
46,987.40
42,932.00
48,491
EBIT
20,785.30
33,413.30
20,462.00
24,116.50
16,451.00
16,601
Unusual Expense
65.00
1,700.00
31.50
-
46.00
-
Non Operating Income/Expense
68.00
90.10
50.80
202.10
1,177.00
12,761
Interest Expense
-
-
-
-
1,423.00
2,675
Pretax Income
20,806.80
35,126.70
20,483.80
24,238.80
16,743.00
6,515
Income Tax
300.00
25.00
175.00
100.00
-
-
Consolidated Net Income
20,506.80
35,151.70
20,658.80
24,338.80
16,743.00
6,515
Net Income
20,506.80
35,151.70
20,658.80
24,338.80
16,743.00
6,515
Net Income After Extraordinaries
20,506.80
35,151.70
20,658.80
24,338.80
16,743.00
6,515
Net Income Available to Common
20,506.80
35,151.70
20,658.80
24,338.80
16,743.00
6,515
EPS (Basic)
0.16
0.27
0.14
0.16
0.11
0.04
Basic Shares Outstanding
126,897.20
130,549.70
146,594.10
154,992.10
156,054.10
157,407
EPS (Diluted)
0.16
0.27
0.14
0.16
0.11
0.04
Diluted Shares Outstanding
126,897.20
130,549.70
146,594.10
154,992.10
156,054.10
157,407
EBITDA
20,292.00
32,189.10
18,892.10
22,255.80
14,347.00
13,877
Non-Operating Interest Income
111.60
76.70
60.50
79.80
-
-
About Antares Pharma
View Profile
